Respiratory and Seasonal Viral Immunisation
Research activity includes influenza vaccination in older adults and RSV immunisation in infants, with attention to immune responses that support protection against respiratory infection and severe disease in early life and later adulthood.
- Influenza vaccine immunogenicity
- RSV prevention in infants
- Age-related vaccine response
The sponsor also examines how timing and early-life protection influence antibody development after vaccination or immunisation.
Bacterial Respiratory Disease Prevention
Clinical research covers pneumococcal vaccination in older adults, focusing on protection against pneumococcal infection and related invasive disease through measurement of antibody responses after immunisation.
- Pneumococcal conjugate vaccination
- Antibody response in older adults
- Invasive pneumococcal disease prevention
These studies address immune responsiveness in advanced age, where prevention of bacterial respiratory disease is especially relevant.
Meningococcal Disease and Serogroup-Specific Immunity
Work in meningococcal immunisation includes evaluation of functional antibodies against multiple serogroups linked to invasive meningococcal disease, including meningitis and sepsis.
- MenA, MenC, MenW and MenY immunity
- Serum bactericidal antibody responses
- Protection against invasive meningococcal disease
The research landscape reflects interest in broad serogroup coverage and functional immune protection.
Paediatric Measles Immunisation
Studies also focus on measles vaccination in infants, including early immunisation in outbreak settings and assessment of the resulting humoral immune response in young children.
- MMR immunisation in infancy
- Measles outbreak response
- Infant antibody development
This area addresses protection of infants who are too young for routine timing of standard measles immunisation.
Paediatric and Adult Vaccine Immunology
Across its trials, RIVM examines how vaccine-induced immunity develops in both healthy infants and older adults, with emphasis on antibody production after preventive vaccination or passive immunisation.
- Humoral immune response
- Preventive immunisation
- Age-specific vaccine protection
The portfolio spans common infectious threats in both paediatric and geriatric populations.
